Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study

Trial Profile

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions
  • Sponsors Aimmune Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.
    • 07 Jun 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Nov 2017.
    • 14 Nov 2016 According to an Aimmune Therapeutics media release, results presented at the 2016 Annual Scientific Meeting of the American College of Asthma, Allergy and Immunology (ACAAI)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top